Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Meridian Bioscience (VIVO) stocks in Canada

Learn how to easily invest in Meridian Bioscience stocks.

Meridian Bioscience is a diagnostics & research business based in the US. Meridian Bioscience stocks (VIVO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $21.7 – an increase of 3.35% over the previous week. Meridian Bioscience employs 702 staff and has a trailing 12-month revenue of around $313.3 million.

How to buy stocks in Meridian Bioscience

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VIVO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Meridian Bioscience stock price (NASDAQ:VIVO)

Use our graph to track the performance of VIVO stocks over time.

Meridian Bioscience shares at a glance

Information last updated 2022-05-12.
Latest market close$24.67
52-week range$17.00 - $28.72
50-day moving average $26.07
200-day moving average $21.81
Wall St. target price$30.00
PE ratio 17.4504
Dividend yield $0 (0%)
Earnings per share (TTM) $1.36

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
OFFER
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get $500 in commission free trades when you fund your account with a minimum of $10,000. Conditions apply. Ends August 31st, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Meridian Bioscience stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Meridian Bioscience price performance over time

Historical closes compared with the close of $24.67 from 2022-05-13

1 week (2022-05-06) -5.91%
1 month (2022-04-14) -11.70%
3 months (2022-02-16) -3.10%
6 months (2021-11-16) 21.29%
1 year (2021-05-14) 29.37%
2 years (2020-05-15) 50.06%
3 years (2019-05-16) 122.45%
5 years (2017-05-16) 67.25%

Is Meridian Bioscience under- or over-valued?

Valuing Meridian Bioscience stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Meridian Bioscience's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Meridian Bioscience's P/E ratio

Meridian Bioscience's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Meridian Bioscience shares trade at around 17x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Meridian Bioscience's PEG ratio

Meridian Bioscience's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.33. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Meridian Bioscience's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Meridian Bioscience's EBITDA

Meridian Bioscience's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $100.3 million.

The EBITDA is a measure of a Meridian Bioscience's overall financial performance and is widely used to measure a its profitability.

Meridian Bioscience financials

Revenue TTM $313.3 million
Operating margin TTM 26.98%
Gross profit TTM $201.1 million
Return on assets TTM 11.97%
Return on equity TTM 19.22%
Profit margin 19.14%
Book value $7.93
Market capitalisation $1 billion

TTM: trailing 12 months

Meridian Bioscience share dividends

We're not expecting Meridian Bioscience to pay a dividend over the next 12 months.

Have Meridian Bioscience's shares ever split?

Meridian Bioscience's shares were split on a 3:2 basis on 13 May 2007. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Meridian Bioscience shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Meridian Bioscience shares which in turn could have impacted Meridian Bioscience's share price.

Meridian Bioscience share price volatility

Over the last 12 months, Meridian Bioscience's shares have ranged in value from as little as $17 up to $28.72. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Meridian Bioscience's is 0.3407. This would suggest that Meridian Bioscience's shares are less volatile than average (for this exchange).

Meridian Bioscience overview

Meridian Bioscience, Inc. , a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site